Thrombin Receptor Antagonism

 

E5555 (Atopaxar) in Japanese Patients with Acute Coronary Syndrome or High Risk Coronary Artery Disease:

      -Trial Overview by Dr. Shinya Goto (ESC 2010)

LANCELOT-ACS: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of a Reversible PAR-1 Thrombin Receptor Antagonist in Patients with Acute Coronary Syndrome

      -Trial Overview by Dr. Michelle O'Donoghue (TCT 2010)

Phase II TRA-PCI Trial: Thrombin Receptor Antagonist Percutaneous Coronary Intervention

      -Results of a Multinational Randomized, Double-Blind, Placebo-Controlled Study of a Novel Thrombin Receptor Antagonist SCH 530348 in Percutaneous Coronary Intervention by Dr. David J. Moliterno

 

Who Are We?    Slide Downloading Policy   Financial Disclosure    We Do Not Promote Off Label Product Use    Copyright    Source of Slides    Editorial Policy    Links Policy    Privacy Policy   Access    CME Programs

© 1999-2009 by Clinical Trial Results .org.  None of the materials on this website may be reproduced, modified, distributed, transmitted, republished, displayed, or performed unless prior written approval is obtained by Clinical Trial Results.  All such requests should be forwarded to Susan J. Marble at smarble@clinicaltrialresults.org. For further information please see the Policy section. Webmaster